Nebula Research & Development LLC Edgewise Therapeutics, Inc. Call Options Transaction History
Nebula Research & Development LLC
- $1.17 Trillion
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding EWTX
# of Institutions
191Shares Held
118MCall Options Held
54.3KPut Options Held
70.1K-
Orbimed Advisors LLC San Diego, CA15.5MShares$238 Million7.26% of portfolio
-
Ra Capital Management, L.P. Boston, MA9.9MShares$152 Million2.84% of portfolio
-
Baker Bros. Advisors LP New York, NY7.31MShares$112 Million0.97% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY6.14MShares$94.3 Million3.76% of portfolio
-
Black Rock Inc. New York, NY6.02MShares$92.3 Million0.0% of portfolio
About Edgewise Therapeutics, Inc.
- Ticker EWTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 63,171,700
- Market Cap $970M
- Description
- Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has c...